System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Laurent Mortier is an expert in Dermatology at Centre Hospitalier Universitaire de Lille (France). As of October 2026, ScienceLeadR ranks Laurent Mortier in the top 1% of experts worldwide for Non-Melanoma Skin Neoplasms, Skin Neoplasms and Melanoma. Laurent Mortier has authored 707 publications, the most recent in 2026, and is an investigator in 65 clinical trials, 13 of them ongoing. SLR score: 2,982 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Laurent Mortier Centre Hospitalier Universitaire de Lille France
2 982 ScienceLeadR Reputation 2982

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2002 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 707

Citations

Citations: 40 858 1st author: 22 Last author: 174 Unique author: 2

Main journals

Ann Dermatol Venereol 196
J Clin Oncol 69
Ann Oncol 38
Annales de dermatologie et de vénéréologie, FMC 30
Eur J Cancer 24

Best Journals

J Clin Oncol 27
Ann Oncol 19
N Engl J Med 11

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Photodynamic Diagnosis of Actinic Keratosis: A Systematic Review.
PMID 42775870 — keratosis, keratosis, actinic, diagnosis		Acta Derm Venereol20260
Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.
PMID 42667537 — safety, melanoma, nivolumab, therapeutics		Dermatol Ther (Heidelb)20260
Successful 15-step desensitization protocol for nivolumab and ipilimumab after a skin-test confirmed anaphylaxis to polysorbate 80: case report.
PMID 42631650 — skin, research design, hypersensitivity, melanoma, excipients, anaphylaxis, skin tests, polysorbates, nivolumab, therapeutics, ipilimumab		Melanoma Res20261
Tele-expertise reduces time to diagnosis for cutaneous melanoma.
PMID 42572456 — melanoma, diagnosis, wounds and injuries		Melanoma Res20260
Development of dual-function optical microneedle lens array for skin cancer treatment by photodynamic therapy.
PMID 42522590 — skin, cells, photochemotherapy, melanoma, neoplasms, therapeutics, nanotechnology, skin neoplasms, microneedle drug delivery		Lab Chip20261

Clinical Studies 65

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 14

By phase:

Phase 3 25
Phase 2 22
N/A 11
Phase 2/Phase 3 3
Phase 1 2
Phase 1/Phase 2 1
Phase 3/Phase 4 1

By status:

Completed 29
Active not recruiting 13
Recruiting 12
Terminated 6
Unknown 5

By type:

Interventional 59
Observational 6

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 3
multicentric5to9 5
multicentricup10 48

Main Topics

Ongoing Clinical Trials

13 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 — melanoma, rna, messenger		Phase 3Active not recruiting2023
Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment
NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma		N/ARecruiting2021
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127)
2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab		Phase 3Recruiting2023
Vitiligo treatment by targeting TYK2 mediated responses
2023-507451-30-00 — vitiligo, therapeutics		Phase 2Active not recruiting2024
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First Line Therapy in Patients With Advanced Melanoma
NCT06697301 — toll-like receptors, safety, melanoma, neoplasms, neoplasm metastasis, therapeutics, toll-like receptor 7		Phase 2/Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS